Sirolimus (rapamycin)

DRUG4 trials

Sponsors

Johns Hopkins University, Boehringer Ingelheim, M.D. Anderson Cancer Center, University of Missouri-Columbia

Conditions

APOE-4 PositiveAdvanced CancerCarcinoma, Non-Small-Cell LungGenetic Predisposition to DiseaseHealthy VolunteerIntermediate UveitisPanuveitisPosterior Uveitis

Phase 1

Sirolimus as Therapeutic Approach to Uveitis

CompletedNCT00908466

Johns Hopkins UniversityUveitis, Intermediate Uveitis, Posterior Uveitis +1

Start: 2009-07-31End: 2013-02-28Updated: 2018-08-20

Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib

CompletedNCT00993499

Boehringer IngelheimCarcinoma, Non-Small-Cell Lung

Start: 2009-10-31End: 2014-09-30Updated: 2015-10-07

Docetaxel and Sirolimus in Patients With Advanced Malignancies

CompletedNCT01054313

M.D. Anderson Cancer CenterAdvanced Cancer

Start: 2010-01-31End: 2014-10-31Updated: 2015-10-07

Effects of Sirolimus on Asymptomatic ApoE4 Carriers

Not yet recruitingNCT07728175

University of Missouri-ColumbiaGenetic Predisposition to Disease, Healthy Volunteer, APOE-4 Positive

Start: 2026-12-01End: 2028-07-07Target: 225Updated: 2026-07-30

Related Papers

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.

2017-03-2220 citations

Assessment of changes in quality of life among patients in the SAVE Study - Sirolimus as therapeutic Approach to uVEitis: a randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis.

2015-04-1816 citations